Heartflow (NASDAQ:HTFL) Coverage Initiated at Piper Sandler

Key Points

• Piper Sandler has initiated coverage of Heartflow (NASDAQ:HTFL), assigning an "overweight" rating with a price target of $38.00, suggesting a potential upside of 20.63% from the previous close.
• Other analysts, including Canaccord Genuity Group, also rated Heartflow with a "buy," setting a price objective of $35.00, indicating a consensus rating of "Buy" with an average price target of $36.33.
• Heartflow’s stock price has ranged from a one-year low of $26.56 to a high of $36.68, opening at $31.50 on the day of the report.

Piper Sandler initiated coverage on shares of Heartflow (NASDAQ:HTFL - Free Report) in a research note published on Tuesday morning, MarketBeat reports. The firm issued an overweight rating and a $38.00 target price on the stock.

HTFL has been the subject of a number of other research reports. Canaccord Genuity Group began coverage on shares of Heartflow in a research note on Tuesday, September 2nd. They set a "buy" rating and a $35.00 target price for the company. Wall Street Zen raised shares of Heartflow to a "hold" rating in a research note on Saturday, August 16th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Heartflow has an average rating of "Moderate Buy" and a consensus target price of $35.80.

Heartflow Trading Down 8.8%

NASDAQ HTFL traded down $3.01 on Tuesday, hitting $31.07. 442,043 shares of the stock were exchanged, compared to its average volume of 878,154. Heartflow has a 52-week low of $26.56 and a 52-week high of $36.68.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.